학술논문

1940P CALIBRATION: Can early changes in circulating tumour DNA (ctDNA) predict durable tumour responses in patients (pts) with advanced esophageal adenocarcinoma (EAC) receiving anti PD-L1 antibody durvalumab (D)?
Document Type
Abstract
Source
In Annals of Oncology September 2020 31 Supplement 4:S1096-S1096
Subject
Language
ISSN
0923-7534